CARDIFF, Calif., March 8, 2012 — NI Research, the publisher of independent and authoritative reviews of the neurotherapeutics area, has released the 2012 edition of the Private CNS Company Review. PCNS provides a unique database of information about the private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders. PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities.
"In an era where many major pharmaceutical companies are still trying to develop a coherent and effective strategy for neuroscience, much of the most creative and promising R&D for neurotherapeutics is being carried out by privately held companies. The 138 companies reviewed in PCNS cover the full gamut of innovation, from those addressing highly innovative albeit risky novel targets, to companies developing clinical-stage modifications of familiar mechanistic themes," notes Harry Tracy, PhD, President of NI Research (http://www.niresearch.com).
"Not all of them are going to be productive; there is both excellence and mediocrity to be found in this group, but any large or midsize pharmaceutical company intending to participate in the next generation of neurotherapeutics must pay close attention to the programs in development by these firms. No other publication focuses on this area with the depth and comprehensiveness of PCNS; it is a unique resource for Business Development teams at companies of any size," said Tracy, who provides consultation services to the neuropharm industry.
The Table of Contents for the 2012 edition of the Private CNS Company Review:
Private CNS Company Fates/Casualties
Private CNS Company Destinations
Private CNS Company Funding 2011
Opportunities by Stage of Development
2012 PCNS Inflection Points
Top Five PCNS Partnering Opportunities
Four PCNS Subsets: Neurotrophic Factors, Novel Pain Mechanisms, Novel Antidepressants, Novel Schizophrenia Drug Mechanisms
Company Reviews:
Accera
AC Immune
Acumen Pharmaceuticals
Adamas Pharmaceuticals
Aestus Therapeutics
Affectis Pharmaceuticals
Afferent Pharmaceuticals
Affiris
Afraxis
AgeneBio
American Life Science Pharmaceuticals
Archer Pharmaceuticals
Arcion Therapeutics
Ariel Pharmaceuticals
ArmaGen Technologies
Astraea Therapeutics
AurimMed Pharma
AviNeuro
Avraham Pharmaceuticals
Axerion Therapeutics
Axon-Neuroscience
Azevan Pharmaceuticals
Bayhill Therapeutics
BioArctic Neuroscience
BioAxone BioSciences
BioChromix Pharma
Biocrea
BrainCells
BrainTact
Cambria Pharmaceuticals
Canbex Therapeutics
Cara Therapeutics
CeNeRx BioPharma
Cerecor
Ceregene
Chaperone Therapeutics
Clera
Cognition Therapeutics
Cognosci
Collegium Pharmaceuticals
CoLucid
CoMentis
Convergence Pharmaceuticals
Cortica Neuroscience
Cyrenaic Pharmaceuticals
Dart Neuroscience/Helicon Therapeutics
Domain Therapeutics
Embera Neurotherapeutics
ENKAM Pharmaceuticals
EnVivo Pharmaceuticals
Envoy Therapeutics
Euthymics Bioscience
Galantos Pharma
Galenea
GeNeuro
Hermo Pharma
Insero Health
Intra-Cellular Therapies
Karuna Pharmaceuticals
KeyNeurotek
Knopp Biosciences
Kyalin Biosciences
Maas Biolab
Mapreg
Marinus Pharmaceuticals
Medeia Therapeutics
MedGenesis Therapeutix
MediProPharma
Mind-NRG
Mithridion
Mnemosyne
M's Science
MSI Methylation Sciences
Naurex
Nautilus Neuroscience
Neuraltus
NeurAxon
Neurim
Neurimmune Therapeutics
NeuroGeneration
Neurogenetic Pharmaceuticals
NeuroHealing
NeuroKin
NeuroKos
Neurolixis
Neurona Therapeutics
Neuronascent
NeuroNova
NeuroP
NeuroPhage
NeuroPore Therapies
Neurotez
NeuroTherapeutics Pharma
Neurotune
New World Laboratories
NoNO Inc.
Noscira
NsGene
Oligomerix
Pharmacofore
PharmaNeuroBoost
PharmatrophiX
Pharmaxon
Pharnext
Prexa Pharmaceuticals
Probiodrug
ProMentis Pharmaceuticals
Proneuron Biotechnologies
Proteostasis Therapeutics
Psyadon Pharmaceuticals
Q Therapeutics
QR Pharma
Receptos
Regenesance
Remedy Pharmaceuticals
ReMYND
ReXceptor
Sage Therapeutics
SanBio
Satori Pharmaceuticals
SCT Spinal Cord Therapeutics
Seaside Therapeutics
Senexis
SenexTa Therapeutics
Sinapis Pharma
SMART Biosciences
Somnus Therapeutics
Sonexa Therapeutics
Spinifex Pharmaceuticals
Synchroneuron
TauRx
TauTaTis
TheraQuest Biosciences
to-BBB
Trigemina
Trophos
Xenome Ltd
Zenobia
On the Cusp …
Programs by Company, Indication, Stage
Company Funding
VC CNS Portfolios
Private CNS Company Review 2012 is the annual, independent review of the private neuroscience company universe. The cost of PCNS 2012 is $4,000 for NeuroPerspective subscribers, $5,000 for nonsubscribers. Startup companies can contact us for pricing options.
About NI Research
NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroPerspective (formerly NeuroInvestment) since 1995; the Private CNS Company Review since 2003; and CNS Therapeutics and Licensing since 2007. NI Research has developed an unmatched information base regarding both publicly and privately held neurotherapeutics companies, and offers M&A/licensing consultation services.
For information, go to http://www.niresearch.com
Blog: http://neurogram.wordpress.com
# # #